Guggenheim sees big upside for Tetraphase


Tetraphase Pharmaceuticals (TTPH +5.3%)  is trading notably higher on the session.

Likely helping the cause is Guggenheim, where analysts initiated the shares at Buy.

Price target is $25, representing upside of around 144% from Tuesday's close.

From other sites
Comments (1)
  • Rhinoish
    , contributor
    Comments (125) | Send Message
     
    Its gonna take a couple years for FDA approval, but $25? eventually yeah it'll get there, if its not bought out
    14 Nov 2013, 02:45 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs